Korro Bio Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Korro Bio Inc 公司

Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.

Korro Bio Inc简介



公司代码KRRO

公司名称Korro Bio Inc

上市日期Oct 03, 2019

CEODr. Ram Aiyar, Ph.D.

员工数量104

证券类型Ordinary Share

年结日Oct 03

公司地址One Kendall Square. Building 600-700

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02139

电话16174681999

网址https://www.korrobio.com/

公司代码KRRO

上市日期Oct 03, 2019

CEODr. Ram Aiyar, Ph.D.

Korro Bio Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Nessan Bermingham, Ph.D.

Independent Chairman of the Board

35.11K

--

Mr. Oliver Dolan

Principal Accounting Officer

21.48K

+21482.00%

Mr. Todd Chappell

Chief Operating Officer

20.13K

+20132.00%

Dr. Ram Aiyar, Ph.D.

President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director

--

Dr. Ali Behbahani, M.D.

Independent Director

--

Dr. Jean-Francois Formela, M.D.

Independent Director

--

Mr. Timothy R. Pearson

Independent Director

--

Mr. Venkat Krishnamurthy, Ph.D.

Senior Vice President - Platform

--

Ms. Stephanie Engels

Senior Vice President - People and Culture

--

Dr. Rachel Meyers, Ph.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Dr. Nessan Bermingham, Ph.D.

Independent Chairman of the Board

35.11K

--

Mr. Oliver Dolan

Principal Accounting Officer

21.48K

+21482.00%

Mr. Todd Chappell

Chief Operating Officer

20.13K

+20132.00%

Dr. Ram Aiyar, Ph.D.

President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director

--

Dr. Ali Behbahani, M.D.

Independent Director

--

Dr. Jean-Francois Formela, M.D.

Independent Director

--

收入明细

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

1.09M

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 2月3日周二

持股股东

股东类型

持股股东

占比

Atlas Venture

12.08%

New Enterprise Associates (NEA)

11.58%

Lynx1 Capital Advisors LLC

7.79%

Driehaus Capital Management, LLC

7.14%

Fidelity Management & Research Company LLC

5.99%

其他

55.43%

持股股东

占比

Atlas Venture

12.08%

New Enterprise Associates (NEA)

11.58%

Lynx1 Capital Advisors LLC

7.79%

Driehaus Capital Management, LLC

7.14%

Fidelity Management & Research Company LLC

5.99%

其他

55.43%

股东类型

持股股东

占比

Investment Advisor

51.04%

Venture Capital

24.12%

Hedge Fund

23.88%

Investment Advisor/Hedge Fund

15.43%

Corporation

5.74%

Research Firm

2.19%

Individual Investor

1.96%

Private Equity

0.34%

Bank and Trust

0.26%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

193

11.05M

117.36%

+1.14M

2025Q3

186

9.33M

99.33%

-1.07M

2025Q2

186

10.38M

110.55%

-200.85K

2025Q1

189

10.53M

112.24%

-76.97K

2024Q4

194

10.26M

109.50%

+485.90K

2024Q3

177

9.16M

98.29%

-245.98K

2024Q2

167

9.06M

97.57%

+507.87K

2024Q1

179

7.52M

93.89%

+737.20K

2023Q4

198

7.18M

91.01%

+1.51M

2023Q3

223

264.10K

35.84%

-47.15K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Atlas Venture

1.14M

12.08%

--

Sep 30, 2025

New Enterprise Associates (NEA)

1.09M

11.58%

--

Sep 30, 2025

Lynx1 Capital Advisors LLC

733.63K

7.79%

+733.63K

--

Dec 23, 2025

Driehaus Capital Management, LLC

671.98K

7.14%

+91.12K

+15.69%

Sep 30, 2025

Fidelity Management & Research Company LLC

563.68K

5.99%

-75.54K

-11.82%

Sep 30, 2025

Platanus Investment LLC

540.16K

5.74%

--

Apr 15, 2025

Point72 Asset Management, L.P.

531.97K

5.65%

-8.11K

-1.50%

Sep 30, 2025

The Vanguard Group, Inc.

395.66K

4.2%

+8.92K

+2.31%

Sep 30, 2025

Cormorant Asset Management, LP

465.00K

4.94%

--

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.05%

Avantis US Small Cap Equity ETF

0.02%

Global X Russell 2000 ETF

0.01%

Proshares Ultra Russell 2000

0.01%

ProShares UltraPro Russell2000

0%

SPDR Portfolio MSCI Global Stock Market ETF

0%

ProShares Hedge Replication ETF

0%

Invesco Dorsey Wright SmallCap Momentum ETF

0%

iShares Russell 2000 Growth ETF

0%

iShares Russell 3000 ETF

0%

iShares Micro-Cap ETF

占比0.05%

Avantis US Small Cap Equity ETF

占比0.02%

Global X Russell 2000 ETF

占比0.01%

Proshares Ultra Russell 2000

占比0.01%

ProShares UltraPro Russell2000

占比0%

SPDR Portfolio MSCI Global Stock Market ETF

占比0%

ProShares Hedge Replication ETF

占比0%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0%

iShares Russell 2000 Growth ETF

占比0%

iShares Russell 3000 ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

公告日期

除权除息日

类型

比率

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1